BUSINESS, CONSUMER SERVICES, AND HOUSING AGENCY EDMUND G. BROWN JR., GOVERNOR

STATE BOARD OF OPTOMETRY 2450 DEL PASO ROAD, SUITE 105, SACRAMENTO, CA 95834 P (916) 575-7170 F (916) 575-7292 www.optometry .ca.gov

Continuing Education Course Approval Checklist

Title:

Provider Name:

Completed Application Open to all Optometrists? Maintain Record Agreemen

Yes t?Yes

No No

Correct Application Fee

Detailed Course Summary

Detailed Course Outline

PowerPoint and/or other Presentation Materials

Advertising (optional)

CV for EACH Course Instructor

License Verification for Each Course Instructor Disciplinary History? Yes No

www.optometry

I

. _, r

: , .. , ''" - . -. . ~. ,-.

or=1~~~$"""","~=;:g::,.,....,;~=ltn=::1,~=1t=:~..,...,,'.~,,,.,-;J~1"""'rnt'-,.tt'./:....,.:Z;;2:""'"'~;~I APPLICATION __..SZ_-0-1 Pursuant to California Code of Regulations (CCR) 1536, the Board will approve con mumg e uca 10n courses after

receiving the applicable fee, the requested information below and it has been determined that the course meets criteria specified in CCR 1536(g).

In addition to the information requested below, please attach a copy of the course schedule and topical outline of the

subject matter. Applications must be submitted 45 days prior to the course presentation date.

Please type or print clearly.

Course Providercontact Information Provider Name {_l~1z:tf. v1Sttln M-&(1 ul 6rfh/1,f

., . fu_t11 /A Vard-et?'kitI

"{Ft) (Middle)IrSt (Last) Provider Mailing Address

. 4r/OO Street ~!2_ g/vltliJ? til_l::!!Yln attachments submitted is true and comet.

////'Yb ---- , t2J /}fb\,~Signature-or Course Provider ',, Date

0 o"'""';''."'".-..~"o..'"''"' y,PT,OMETR'J . !. ,; '" .' ,, .' . l '

GOVERNOR EDMUND G. BROWN JR.

-, .STATE BOARD OF OPTOMETRY

, 2450 DEL PASO ROAD, SUITE 105, SACRAMENTO, CA 95834

__ . Q .1 P (916) 575-7170 F (916) 575-7292 www.optometry.ca.gov .. i v' 0 1 ~ l

CONTINUING EDUCATION COURSE IA:l~.Ni::::l~rl:::---r---:---:-rA-:-m-o-un-,t

1---:,-e';-2-i--'3'-_-~-~-+-5-C/_D_t/.._r:J

Form CE-01, Rev. 2/16 1

r7

http:www.optometry.ca.govhttp:or=1~~~$"""","~=;:g::,.,....,;~=ltn=::1,~=1t=:~..,...,,'.~,,,.,-;J~1"""'rnt'-,.tt

Course Title: Cornea Ectasias: Keratoconus, Pellucid Marginal Degeneration, and

Post-Lasik Ectasia (New Treatment Options Part 2)

Course Presentation date: 10/12/16

Speakers: Jennifer Wu, MD

Target Audience: This lecture is intended for optometrist seeking continuing

education

Course description: This course reviews for attendees' new treatment options for

moderate to severe Keratoconus patients. Discussion of refractive treatment

options in combination with corneal cross linking for cornea ectasias and

advanced cornea transplant options.

CE credits: 1 CE units

2

8/23/2016

1~ CORNEA ECTASIAS: KERATOCONUS, PELLUCID MARGINAL DEGENERATION, AND POST-LASIK ECTASIA (NEW TREATMENT OPTIONS PART 2)

JENNIFER LEE WU, MD

CORNEA, ANTERIOR SEGMENT, REFRACTIVE SPECIAUST

COASTAL VISION MEDICAL GROUP

2 ~ OBJECTIVES UNDERSTAND NEW TREATMENT OPTIONS FOR MODERATE-SEVERE KERATOCONUS

(KCN) LEARN ABOUT REFRACTIVE TREATMENT OPTIONS IN COMBINATION WITH CORNEAL

CROSS UNKING FOR CORNEA ECTASIAS LEARN ABOUT ADVANCED CORNEA TRANSPLANT OPTIONS

3~

1' KERATOCONUS 2 PELLUCID MARGINAL DEGENERATION 3 CLASSIC "CRAB-CLAW" APPEARANCE ON TOPOGRAPHY

KMAX INFERIOR TO CORNEAL APEX THINNEST PACHYMETRY POINT IS INFERIOR TO KMAX

4 INFERIOR STEEPENING ON TOPOGRAPHY KMAX CLOSE TO CORNEAL APEX, USUALLY SUGHTLY INFERIOR-TEMPORAL THINNEST PACHYMETRY POINT CORRESPONDS TO KMAX

4[Qj 1 KERATOCONUS 2 PELLUCID MARGINAL DEGENERATION

s~ KERATOCONUS DISEASE STAGING

6~ NEW ADVANCED TREATMENTS FOR KERATOCONUS

CORNEA COLLAGEN CROSS-UNKING (CXL)- SLOWS OR STOPS PROGRESSION OF KERATOCONUS

INTRACORNEAL RINGS (INTACS) PHAKIC IOL- VISIAN ICL (IMPLANTABLE COLLAMER LENS) TOPOGRAPHY-GUIDED PRK FEMTOSECOND-LASER ENABLED CORNEAL TRANSPLANTS

7~ INTRACORNEAL RINGS

ag NEW ADVANCED TREATMENTS FOR KERATOCONUS CORNEA COLLAGEN CROSS-UNKING- SLOWS OR STOPS PROGRESSION OF

KERATOCONUS INTRACORNEAL RINGS (INTACS) PHAKIC IOL- VISIAN ICL (IMPLANTABLE COLLAMER LENS)

3 1

8/23/2016

TOPOGRAPHY-GUIDED PRK FEMTOSECOND-LASER ENABLED CORNEAL TRANSPLANTS

9 Q PHAKIC INTRAOCULAR LENS VISIAN ICL (IMPLANTABLE COLLAMER LENS), TORIC OPTION NOT CURRENTLY

AVAILABLE IN THE US A SYNTHETIC LENS THAT IS PERMANENTLY IMPLANTED IN THE EYE BEHIND THE IRIS

AND IN FRONT OF THE NATURAL LENS FDA APPROVED DECEMBER 2005 FOR ADULTS 21-45 YEARS WITH STABLE REFRACTION FOR 1 YEAR CORRECTION OF MYOPIA RANGING FROM -3 TO -15 DIOPTERS (D) WITH LESS THAN

OR EQUAL TO 2.SD OF ASTIGMATISM AT THE SPECTACLE PLANE

10 ~ NEW ADVANCED TREATMENTS FOR KERATOCONUS CORNEA COLLAGEN CROSS-LINKING- SLOWS OR STOPS PROGRESSION OF

KERATOCONUS INTRACORNEAL RINGS (INTACS) PHAKIC IOL- VISIAN ICLTM (IMPLANTABLE COLLAMER LENS) TOPOGRAPHY-GUIDED PRK FEMTOSECOND-LASER ENABLED CORNEAL TRANSPLANTS

11~

12~ TOPOGRAPHY-GUIDED PRK IN THE US WAVELIGHT ALLEGRElTO WAVE EYE-Q EXCIMER LASER SYSTEM (ALCON), FDA

APPROVED SEPTEMBER 2012 FOR LASIK TREATMENT ALLEGRO TOPOLYZER ALONG WITH THE SOFTWARE TOPOGRAPHY-GUIDED CUSTOM

ABLATION TREATMENT TOPOGRAPHY-GUIDED ABLATION DIFFERS FROM STANDARD ABLATIONS IN THAT IT

AIMS TO LEVEL OUT THE CORNEAL SURFACE USING A BLENDING OF MYOPIC FLATTENING AND HYPEROPIC STEEPENING, RESULTING IN OVERALL LESS TISSUE REMOVAL AND A SMOOTHER CORNEA SURFACE

"IN WAVEFRONT-GUIDED ABLATION, THE MOUNTAINS ARE SIMPLY FLATTENED, AND REQUIRES A SIGNIFICANT AMOUNT OF FLATTENING TO EQUALIZE THE WHOLE CORNEA''

"IN TOPOGRAPHY-GUIDED ABLATION, THE COMBINED ACTION ON CONE APEX FLATTENING WHILE THE REST OF THE CENTRAL CORNEA IS STEEPENED IS THE UNIQUE MODALTIY THAT THE TREATMENT OFFERS."

NOT FDA APPROVED FOR USE IN PATIENTS WITH IRREGULAR CORNEAS, THIS WAS PRIOR TO FDA APPROVAL OF CORNEA CROSS-LINKING

13 Q CLINICAL EFFECT OF CXL CROSS-LINKING IS SUCCESSFUL IN STOPPING THE DISEASE FROM PROGRESSING IN

CLOSE TO 98 PERCENT OF PATIENTS 70% MEAN KERATOMETRY REGRESSION OF 2 D AT THE CORNEAL PLANE AND A

REGRESSION OF 1.14 D OF THE MANIFEST SPHERICAL EQUIVALENT REFRACTIVE ERROR

4 2

8/23/2016

VISUAL ACUITY IMPROVED SLIGHTLY IN 65% OF THE EYES

14 ~ CORNEAL CXL IN THE US AVEDRO AND CXL-USA COMPANIES BEGAN CORNEA COLLAGEN CROSS-LINKING

CLINICAL TRIALS IN THE US IN 2008 FOR FDA APPROVAL APRIL 2016 AVEDRO KXL SYSTEM+ PHOTOENHANCERS RECEIVES FDA APPROVAL FOR TREATMENT OF PROGRESSIVE KERATOCONUS

JULY 2016 AVEDRO KXL SYSTEM + PHOTOENHANCER RECEIVES FDA APPROVAL FOR TREATMENT OF CORNEA ECTASIA FOLLOWING REFRACTIVE SURGERY

1s[g) TOPO-GUIDED PRK IN COMBINATION WITH CXL CAN BE PARTICULARLY USEFUL IN PATIENTS WITH IRREGULAR CORNEA SURFACE

SUCH AS CORNEA ECTASIA (KERATOCONUS AND PELLUCID MARGINAL DEGENERATION), POST-KERATOPLASTY IRREGULAR ASTIGMATISM, PREVIOUS INJURIES OR CORNEAL SCARS, AND ECTASIA FOLLOWING LASER VISION CORRECTION, LESS TISSUE REMOVAL TO ACHIEVE REFRACTIVE OUTCOME.

RECOMMEND CROSS-LINKING PATIENTS FIRST, ONCE CORNEAL STABILDY ACHIEVED, THEN CONSIDER TOPO-GUIDED PRK, AIM TO REMOVE NO MORE THAN 50UM OF TISSUE.

16~ TOPO-GUIDED PRK IN COMBINATION WITH CXL CASE REPORT FROM JOHN KANELLOPOULOS IN ATHENS, GREECE 2007 26 YO MALE WITH BILATERAL PROGRESSIVE KERATOCONUS UNABLE TO TOLERATE

CTL AFTER 8 YEARS BCVA 20/15 OD (-0.75 -0.75 X 165) AND 20/50 OS (-3.75 -4.50 X 155)

KMAXOD 44.25; KMAXOS 48.50

PT GIVEN CHOICE OF PENETRATING KERATOPLASTY ("GOLD-STANDARD'') OR

EXPERIMENTAL TREATMENT (CXL + TOPO-GUIDED PRK) PT UNDERWENT EPITHELIUM-OFF CXL IN OS, THEN 12 MONTHS LATER TOPO-GUIDED

PRK USING ALLEGRElTO-WAVE TOPOGRAPHY GUIDED CUSTOMIZED PROGRAM PRK PLANNED TREATMENT FOR UNDER CORRECTION: SPHERE -2.SOD AND

ASTIGMATISM -3.00D POM#l AFTER TREATMENT 20/20 SC (MRX PLANO -0.50 X 150), VA REMAINED STABLE

AT 12 MONTH FOLLOW-UP

17 ~ DISADVANTAGES TOPOGRAPHY-GUIDED PRK TOPO-GUIDED PRK TAKES A LONG TIME TO PERFORM NEED TO GET SEVERAL RELIABLE MEASUREMENTS AND ACCOUNT FOR PUPIL SIZE NEW ALGORITHMS NEED TO BE DEVELOPED FOR TOPO-GUIDED PRK AFTER CXL

1a ~ COMBINED TREATMENTS FOR MILD-MODERATE KCN CORNEA COLLAGEN CROSS-LINKING + SCLERAL LENS CORNEA COLLAGEN CROSS-LINKING + INTACS CORNEA COLLAGEN CROSS-LINKING + VISIAN ICL + TOPO-GUIDED PRK TO

CORRECT ASTIGMATISM CORNEA COLLAGEN CROSS-LINKING + TOPO-GUIDED PRK

5 3

8/23/2016

19~ DISEASE STAGING

20~ POST-REFRACTIVE SURGERY ECTASIA FEARED COMPLICATION OF LASER REFRACTIVE SURGERY POST-LASIK, POST-PRK, POST-RK DEFINillON % OF PATIENTS

21 ~ CORNEAL CXL IN THE US AVEDRO AND CXL-USA COMPANIES BEGAN CORNEA COLLAGEN CROSS-LINKING

CLINICAL TRIALS IN THE US IN 2008 FOR FDA APPROVAL APRIL 2016 AVEDRO KXL SYSTEM + PHOTOENHANCERS RECEIVES FDA APPROVAL FOR TREATMENT OF PROGRESSIVE KERATOCONUS

JULY 2016 AVEDRO KXL SYSTEM+ PHOTOENHANCER RECEIVES FDA APPROVAL FOR TREATMENT OF CORNEA ECTASIA FOLLOWING REFRACTIVE SURGERY

22~ TREATMENTS FOR POST-REFRACTIVE ECTASIA STABILIZE CORNEA WITH COLLAGEN CROSS-LINKING FIRST THEN CONSIDER VISION

CORRECTION OPTIONS CORNEA COLLAGEN CROSS-LINKING + SCLERAL LENS CORNEA COLLAGEN CROSS-LINKING + VISIAN ICL + TOPO.;GUIDED PRK TO

CORRECT ASTIGMATISM CORNEA COLLAGEN CROSS-LINKING + TOPO-GUIDED PRK

23~ TECHNOLOGY AND INNOVATION: EXPANDING RANGE OF REFRACTIVE SURGERY CANDIDATES NEW MODALITIES FOR EARLY DIAGNOSIS OF ECTASIA- HIGHER RESOLUTION TOPOGRAPHY(PENTACAM)

NEW TREATMENTS TO STOP DISEASE PROGRESSION- CORNEA COLLAGEN CROSSLINKING

NEW TECHNOLOGIES FOR VISION CORRECTION- TOPOGRAPHY-GUIDED PRK

24~

2s[g

26~

CASE #3 18 YO MALE, RAPID CHANGING GLASSES RX FOR LAST 3 YEARS UNABLE TO IMPROVE BCVA BEYOND 20/70 AT LAST OPTOMETRIST VISIT REFERRED FOR KERATOCONUS SUSPECT EVALUATION

27[g) STANDARD TREATMENTS REGIMENTS FOR CORNEA ECTASIA MEDICAL

VISION CORRECTION (RIGID GAS-PERMEABLE OR SCLERAL CONTACT LENS) SURGICAL

CORNEAL TRANSPLANT FOR CONTACT LENS INTOLERANCE OR CORNEAL SCARRING UP TO 20% OF THE PATIENTS WITH KERATOCONUS PROGRESS TO THE EXTENT THAT PENETRATING KERATOPLASTY IS INDICATED

6 4

8/23/2016

2a~ NEW ADVANCED TREATMENTS FOR CORNEA ECTASIA

CORNEA COLLAGEN CROSS-LINKING- SLOWS OR STOPS PROGRESSION OF KERATOCONUS

INTRACORNEAL RINGS (INTACS) PHAKIC IOL- VISIAN ICL (IMPLANTABLE COLLAMER LENS) TOPOGRAPHY-GUIDED PRK FEMTOSECOND-LASER ENABLED CORNEAL TRANSPLANTS (FLEK)

29 ~ CONTRAINDICATION FOR KCN CXL CORNEAL SCARRING (APICAL OR HYDROPS) CENTRAL CORNEAL THICKNESS < 400UM (CONCERN FOR DAMAGE TO ENDOTHELIUM

AND LENS) MAXIMUM CORNEAL TOPOGRAPHY > 58D HISTORY OF VIRAL CORNEAL INFECTION

30~ LAYERSOFTHECORNEA

31 ~ CORNEA TRANSPLANT OPTIONS

PENETRATING KERATOPLASlY (PKP) FULL THICKNESS SCAR, HEALED HYDROPS

DEEP ANTERIOR LAMELLAR KERATOPLASlY (DALK) ANTERIOR SCARRING WITH PRESERVED DECEMET'S MEMBRANE +

ENDOTHELIUM FEMTOSECOND LASER-ENABLED KERATOPLASlY (FLEK) OR INTRALASE ENABLED

KERATOPLASlY (IEK) CAN BE COMBINED WITH DALK OR PKP

32~ CORNEA TRANSPLANT STATISTICS

33~

34~

35 [Q) DALK VIDEO

36 Q ADVANTAGES OF DALK

REDUCES ENDOTHELIAL CELL LOSS LONG-TERM SURVIVAL ALLOWS LARGER GRAFTS LESS IMMUNE REJECTION

37[g FEMTOSECOND LASER ENABLED KERATOPLASTY (FLEK)

38~

39~

7 5

8/23/2016

40~

41 ~ THANK YOU! QUESTIONS? JENNYWU@COASTAL-VISION.COM

8 6

mailto:JENNYWU@COASTAL-VISION.COM

.

8/23/2016

) .o OBJECTIVES

CORNEA ECTASIAS: KERATOCONUS, PELLUCJDMARGINAL DEGENERA.TION,AND

. .. . .POST-LASIK ECTASIN . ...

(NEW TR~ATMENTOPTl()NS PART 2) JENNIF~R tEE WU, MD

co~1~EA; ~~T~.~16Rs~~'~kN~f~-~f-.RA2r6~ sP~~/A~is'.

c'?~SrAL\11~1.o'N MED!CAl"~RouP

, J~o .. .J\.;;;;./o \~ \...;.,;,/' KERATOCONUS PELLUCID MARGINAL DEGENERATION-J

e . i55D

-' . ' . .

. ,

~~ 9FlHE CENJRJ.l. 0F'

.

8/23/2016

'.J~INTRACORNEAL RINGS G ~ 0 FDA approved INTACS July 2014 under 0 NEW ADVANCED TREATMENTS FOR KERATOCONUS Humanitarian Deyice Exemption (HOE}

program as rn~rmedlote Procedur.e to ..

postpone ~~rneol tronsPla"n! and attow.~_~tfE:_r.

CTLfi!Jing . .. :

Patients> 21yrs ,: .. : ,'

Perlp~_er~ipCl_chynlefr)' >4:5~um

'No corneal scarr(~g

.u~G 'Ct

i;, PHAKIC INTRAOCULAR

:

LENS

; ;:- Yl.?IAN !CL 11MPJ..NrA~LEC?~~ LENS), ~oRtc ~~r10N N~r CURRENTLY AVAILABLE IN THE US

:,\.. ~ S~N~HRi~-LE~~ T~.i.t-i~ PERMANENTLY,;;!ANTED [t~.._fH~ EYE"

eeH}ND-_THE IRI~ ANb.1N FRONT_ OFT!-i; r:v-1.u~q.eN~

:Y)ttr:it::~t~t::t:::~ABLE.,Ji:oNFORl;~. ~~:~~~t~::Jt1tc:ct~;:h:i?i/1.~~o'~~ix;i~:> '

LEP~~e:-',\' >' ;;'.:.',::.;.,.;. ;"}j

" O

U\,/o J"-6 u~ TOPOGRAPHY-GUIDED PRK IN THE US

. . ' : t~~~RffioWAVE m_.Q EXOMER LASER SYSTEM (ALCON);_~oA APPROI/ED_SEPTEMBiR~012.FOR

' AUE011:o roPOiVZER ~~Nci WITH 'rHE soFTWAREfoPoGRAPw'-ouioW.Clls,oM~lAT10N TREATMENT ~, TdP~o~~Hr.GUIDEDABlAT)ClN DIFFERS FR~MSTANDAA~ AllLATI9Ns {NlHA.T 11' ~Ms To~o~r lHE co'RNEAt .

sRFACE USING.A8U:N0tNG OF_MYci_!'ICFl.A"f"!"ENING AND HYPEROPJCs,:tEPENtNO. RSUL11NG IN OVc~ lESS TISSUEREMOVAi.ANOASMOOltlERCORNEASURFAC . - . "

?~ ~iN WAVEfll:o~.CluiOioABlATION.1HE MOUNTAiNsARe siMPi.vFlAn""E~u), AN~ REOlmnAs10N1F1C'.ANrA,,10u'Nf-6f': 'FlATIENINGTOEQUAUZElHE'NHOlECORNU.- ' - ,. . - .

.~6::.o::Et~~~E~~r:itti~:::r~:EA~c~~/4~::.!~~l~-o"1~~-lHE NOT FDA APPROVED FoR"U~e ;~ P~TIENTS",wi,H i~REGuV.iCORNE/4 ]li;~ w~ ~RI011: TO FDAAPPROVAl. 0

CORNEACROSS.UNKING .,, ..., .,,,,.,,,':. ," '

10 2

http:r:v-1.u~q.eN

8/23/2016

... 1 ~J \~ G

CLINICAL EFFECT OF CXL CORNEAL CXL IN THE US

. ... ...; . / AVEDRO AND ~-USAi:ciMPANIES BEGAN CORNEA COLLAGEN CROSS-UNKJN'G CUNl~lRIALS l~nie f : .

~: c~oSS:uNK1NG Is SUCCESSFUL IN STOPPING THE DISEASE FROM PR6GRess1NG 1N ct.ose~o .'; . 98 PERceNr'OF PATIENTs

vu o..; .COMBINED TREATMENTS FOR MILD-MO[?ERATE KCNv .. DISADVANTAGES TOPOGRAPHY-GUIDED PRK

, TOPO-GUIDED PRK TAKES A LONG TIMETO PERFORM

NEEo.-~6'o:ei SEVERAL RELl~BLE-~~~UREMENTSAND ACco"u.NT.FOR PUPIL"SIZ~ ~ CoRNEA COLLAGEN cRoss.LINKtNG + sa~RAL ieNs ,, 2~~~~A c~u;:GEN CROss-~NKING. + rNTAC:s'

11 3

8/23/2016

() Pachymetry Clinical

Findings i~oy b~-n~,.:.;~I None

steepening, 500 _:Forme

:Fruste

DISEASE STAGING

Topography Keratometry

astigmatism

Inferior steepening Kmox400um Fleisher Ring, apparent, 5-8D of Vogt's Strea

.:.~~.lgm~tls~. ..... ...,....... . .

8-1 OD of Irregular Kmox

CONTRAINDICATION FOR KCN CXL

.c_e.~l'RAL co~NEALJH1cKNesS. .,.,:,

13 5

8/23/2016

. . ) \_;,/_ . ~ u J~

:;. :;, G G CORNEA TRANSPLANT OPTIONS 6 CORNEA TRANSPLANT STATISTICS

PENETRATING KERATOPLASTY {PKP) , ,. ~ Fllll.)ttl

8/23/2016

IEK-DALK G

~. 1.Roclplentbodzlgzagculwilh,;;""FEMTOSECOND LASER ENABLED KERATOPLASTY (FLEK) I':' , fomtosocond loser

: -~.... ... -

~

:;~ .. .

~ - ~

i ~

;~/

-.~ 2.Pal!ontlransporle~l.oOR,'f!nci_:

pro-cutplano.80-90%deplhand-: lno blg bubble lo~h~lqUe, lo':

dluo,t.~11'.trom~; -,

: .}: ~o~~ots._i:n~m~~ano,and'._ ,

.,'.:._;:,d~:~~:.::~s=~::1;::h~~zag' 'C0nf19Urallon

IEK-DALK

,'J'.. , .. ;. v"'

15 7

'o Jennifer Lee Wu, M.D. Cornea, Cataract, and Refractive Specialist

Coastal Vision Orange Telephone: (714)771-1213 293 South Main Street, Suite 100 Fax: (714) 771-7126 Orange, CA 92868 Email: jennywu@coastal-vision.com

Education:

2005 B.S. in Molecular, Cellular, Developmental Biology Yale College, New Haven, Connecticut

2009 M.D. Yale University School of Medicine, New Haven, Connecticut

Postdoctoral Training:

2009-10 Internship in Internal Medicine Yale New Haven Hospital, New Haven, Connecticut

2010-13 Residency in Ophthalmology Doheny Eye Institute/LAC-USC Medical Center, Los Angeles, California

2013-14 Clinical Fellowship in Cornea and External Disease Doheny Eye Institute/University of Southern California, Los Angeles, California

Board Certification:

2014 Diplomat, American Board of Ophthalmology

Medical Licensure:

2011 California

2014 Oklahoma

Academic Appointments:

2014- 16 Clinical Assistant Professor in Cornea and External Disease and Refractive Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

2013-14 Clinical Instructor in Ophthalmology Keck Medical Center at University of Southern California, Los Angeles, California

Private Practice:

2016-Present Coastal Vision Medical

16

mailto:jennywu@coastal-vision.com

Jennifer Lee Wu, M.D.

Teaching Experience:

Teaching medical students, residents, and fellows in the eye clinic and operating room Presenting lectures on cornea and external disease to ophthalmology residents

Mentoring Experience:

Mentoring multiple medical students and residents in clinical research project design and manuscript preparation resulting in publications and conference presentations

Participating faculty mentor for American Medical Women's Association at University of Oklahoma- role model for female medical students and undergraduate pre-medical students

Honors and Awards:

2005 Edgar Boell Prize, Yale College

A warded best senior thesis in the Health Sciences

2009 Farr Research Scholar, Yale University School of Medicine

A warded honors medical thesis

2012 ARVO National Eye Institute Travel Grant, National Eye Institute

A warded grant for outstanding research abstract

2012 Henry & Lilian Nesburn Award, Henry & Lilian Nesburn Foundation

Awarded best resident research manuscript

2013 Doheny Resident Research Award, Doheny Eye Institute

Awarded exceptional ARVO presentation

Peer Reviewed Publications:

Articles

1. Mckay T, Hjortdal J, Sejersen J, Asara J, Wu JL and Karamichos D. Endocrine and

Inflammatory Factors in Keratoconus: Role ofHormones in the Stromal

Microenvironment. EMBO reports. Accepted for publication April 2016.

2. Royer D, Gurung H, Jinkins J, Geltz J, Wu JL, Halford W, and Carr DJ. A Highly

Efficacious HSV-1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal

Immunopathology Via Humeral. Journal ofVirology. Accepted for publication March

2016.

3. Lee JC, Wang MY, Damodar D, Sadun AA, Sadda SR. Headache and whiteout vision as the presenting symptoms in a case ofTakayasu Retinopathy. Retinal Cases & Brief Reports. 2014; 8(4):273-275.

4. Lee JC, Chiu G, Bach D, Irvine J, Heur JM. Functional and visual improvement of the

Prosthetic Replacement ofthe Ocular Surface Ecosystem (PROSE) for irregular

astigmatism. Cornea. 2013; 32(12):1540-1543.

5. Lee JC, Wong B, Srinivas S, Sadda SR, Huang D, Fawzi, AA. Doppler Fourier-domain optical coherence tomography measurement ofthe effect ofpanretinal photocoagulation on retinal blood flow in poorly controlled diabetic proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 2013; 54(9):6104-6111.

2

17

1

'' Jennifer Lee Wu, M.D.

6. Khine, K, Lee, JC, Hwang, J, Francis, BA, Boyer, DS. Methyl-Sulfonyl-Methane (MSM)-Induced Acute Angle Closure. Journal ofGlaucoma. 2013; November 14. (Epub ahead ofprint)

7. Lee JC and Shields MB. Horizontal Deviation of Retinal Nerve Fiber Layer Peak Thickness with Stratus Optical Coherence Tomography in Glaucoma Patients and Glaucoma Suspects. Journal ofGlaucoma. 2010; 19:299-303.

8. Lee JC, Prado HS, Diniz JB, Miguel EC, Leckman JF, Rosario MC. Perfectionism and Sensory Phenomena: Possible Phenotypic Components of Obsessive-Compulsive Disorder. Comprehensive Psychiatry. 2009; 50:431-436.

9. Lee JC and Salchow DJ. Myelinated retinal nerve fibers associated with hyperopia and amblyopia. Journal ofAAPOS. 2008; 12: 418-419.

10. Prado HS, Rosario MC, Lee JC, Hounie AG, Shavitt RG, Miguel EC. Sensory Phenomena in Obsessive-Compulsive Disorder and Tic Disorders: a review ofthe literature. CNS Spectrums. 2008; 13: 425-432.

Presentations:

1. ARVO 2016, Seattle, Washington 2. ARVO 2013, Fort Lauderdale, Florida 3. ARVO 2012, Fort Lauderdale, Florida 4. Yale Medical School Student Research Day 2009, New Haven, Connecticut

Professional Memberships:

American Academy of Ophthalmology (AAO)

Association for Research in Vision and Ophthalmology (ARVO)

Cornea Society

American Society of Cataract and Refractive Surgery (ASCRS)

Oklahoma Academy of Ophthalmology (OAO)

Languages:

Fluent in Spanish (Spoken) Fluent in Chinese (Mandarin) (Spoken)

Community Service:

Volunteer Alumni Interviewer for Yale College Admissions

3

18

CHECKLIST CE Course Approval RequestCornea Ectasias-Keratoconus Pellucid Marginal Degeneration and Post Lasik Ectasias (New Treatment Options Part 2)

Text1: Cornea Ectasias: Keratoconus Pellucid Marginal Degeneration, & Post-Lasik Ectasias (New Treatment Options Part 2) Text2: Coastal Vision Medical Group c/o Gina Valdemar Check Box1: YesCheck Box11: YesCheck Box10: Check Box9: YesCheck Box8: YesCheck Box7: YesCheck Box6: YesCheck Box5: Check Box4: YesCheck Box2: YesCheck Box3: Check Box12: YesCheck Box13: Check Box14: Yes